An observational study in Abdominal Aortic Aneurysm, Arterial Stiffness and Left Ventricle Remodeling, sponsored by Josip Juraj Strossmayer University of Osijek. Enrolling by invitation at 1 site in Croatia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-05.
Sponsored by Josip Juraj Strossmayer University of Osijek · Observational
Abdominal aortic aneurysm (AAA) is associated with a high burden of cardiovascular morbidity and mortality. Although endovascular aneurysm repair (EVAR) has become the preferred treatment for many patients with infrarenal AAA because of its lower perioperative risk, its impact on arterial stiffness and cardiac function remains insufficiently understood. Experimental and clinical evidence suggests that endograft implantation may increase aortic stiffness by reducing aortic compliance, potentially altering ventricular-arterial coupling and contributing to left ventricular remodeling and dysfunction.
This prospective observational study aims to evaluate the effects of elective EVAR on aortic stiffness, left ventricular structure and function, and circulating biomarkers of myocardial stress and extracellular matrix remodeling. Patients with infrarenal AAA scheduled for elective EVAR will be assessed before the procedure and at 48 hours, 6 months, and 12 months after intervention. Aortic stiffness will be assessed using estimated carotid-femoral pulse wave velocity (cfPWV), while left ventricular function and remodeling will be evaluated by transthoracic echocardiography, including global longitudinal strain (GLS). Circulating NT-proBNP and MMP-3 concentrations will also be measured.
The study will provide insight into the cardiovascular effects of EVAR and may improve understanding of procedure-related changes in arterial stiffness and cardiac remodeling, thereby supporting better long-term cardiovascular risk assessment and postoperative management in patients undergoing EVAR.
467 studies on the registry are indexed under Aortic Aneurysm, Abdominal; 99 are open to participants now.
This study's planned enrollment of 60 is below the median of 165 across 217 observational studies indexed under Aortic Aneurysm, Abdominal.
Browse Aortic Aneurysm, Abdominal studies →Josip Juraj Strossmayer University of Osijek is the lead sponsor of 26 studies on the registry; 9 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Adult patients with abdominal aortic aneurysm (AAA) scheduled for elective endovascular aneurysm repair (EVAR) will be prospectively enrolled. The study population will include patients undergoing standard-of-care EVAR, who will be followed longitudinally to assess changes in arterial stiffness, cardiac function, and circulating biomarkers before and after the procedure.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients undergoing endovascular aneurysm repair (EVAR) with assessment of arterial stiffness and cardiac function before the procedure and during follow-up (2 days, 6 months, and 12 months after EVAR).
Change in arterial stiffness after endovascular aneurysm repair (EVAR)
Change in arterial stiffness after endovascular aneurysm repair (EVAR)
Time frame: Baseline (pre-EVAR) to 12 months after EVAR (2 days, 6 months, 12 months)
Early and long-term changes in arterial stiffness after EVAR
Changes in PWV at 2 days, 6 months, and 12 months after EVAR compared with baseline.
Time frame: Baseline, 2 days, 6 months, 12 months
Change in left ventricular ejection fraction (LVEF)
Changes in left ventricular ejection fraction following endovascular aneurysm repair (EVAR), assessed by transthoracic echocardiography.
Time frame: Baseline, 2 days, 6 months, 12 months
Changes in circulating biomarkers after EVAR
Changes in circulating biomarkers associated with vascular function, inflammation, and cardiovascular risk after EVAR.
Time frame: Baseline, 2 days, 6 months, 12 months
Change in left ventricular filling pressure (E/e')
Changes in the E/e' ratio, an echocardiographic marker of left ventricular filling pressure and diastolic function, following EVAR.
Time frame: Baseline, 2 days, 6 months, 12 months
Change in left atrial volume index (LAVI)
Changes in left atrial volume index following EVAR, assessed by transthoracic echocardiography.
Time frame: Baseline, 2 days, 6 months, 12 months
Change in left ventricular end-diastolic volume (LVEDV)
Changes in left ventricular end-diastolic volume following EVAR, assessed by transthoracic echocardiography.
Time frame: Baseline, 2 days, 6 months, 12 months
Change in left ventricular global longitudinal strain (LV GLS)
Changes in left ventricular global longitudinal strain, a sensitive marker of left ventricular systolic function, following EVAR.
Time frame: Baseline, 2 days, 6 months, 12 months
Change in left atrial reservoir strain (LA reservoir strain)
Changes in left atrial reservoir strain following EVAR, assessed using speckle-tracking echocardiography.
Time frame: Baseline, 2 days, 6 months, 12 months
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Josip Juraj Strossmayer University of Osijek